Soleno Therapeutics (SLNO) Depreciation & Amortization (CF) (2013 - 2026)
Soleno Therapeutics (SLNO) reported Depreciation & Amortization (CF) of $514000.0 for Q1 2026, up 1.98% year-over-year from $504000.0 in Q1 2025, and up 0.98% quarter-over-quarter from $509000.0 in Q4 2025.
Soleno Therapeutics (SLNO) Depreciation & Amortization (CF) (2013 - 2026) Analysis & Trends
Soleno Therapeutics (SLNO) has 14 years of Depreciation & Amortization (CF) data on file, last reported at $514000.0 in Q1 2026.
- Depreciation & Amortization (CF) for Q1 2026 came in at $514000.0, up 1.98% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.0 million (up 1.3% YoY), and the FY2025 annual result was $2.0 million, up 1.51% from the prior year.
- Depreciation & Amortization (CF) advanced to $514000.0 in Q1 2026 per SLNO's latest filing, from $509000.0 in the prior quarter.
- Over five years, Depreciation & Amortization (CF) peaked at $514000.0 in Q1 2026 and troughed at $488000.0 in Q4 2022.
- A 5-year average of $496470.6 and a median of $492000.0 in 2022 frame the typical range for Depreciation & Amortization (CF).
- The sharpest annual moves came in 2022 and 2024: Depreciation & Amortization (CF) fell 0.81% in 2022, then advanced 2.86% in 2024.
- A 5-year view of Depreciation & Amortization (CF) shows it stood at $488000.0 in 2022, then grew by 0.2% to $489000.0 in 2023, then gained by 2.86% to $503000.0 in 2024, then grew by 1.19% to $509000.0 in 2025, then gained by 0.98% to $514000.0 in 2026.
- Business Quant data shows SLNO's Depreciation & Amortization (CF) at $514000.0 in Q1 2026, $509000.0 in Q4 2025, and $502000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 1,395.22 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1,330.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 55.90 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 429,663.65 |
| 10 | Soleno Therapeutics | 2.76 Bn | 2.51 Bn | 93.41 Mn | 514,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 514,000.00 |
| Mar 31, 2026 | 514,000.00 |
| Dec 31, 2025 | 509,000.00 |
| Dec 31, 2025 | 509,000.00 |
| Sep 30, 2025 | 502,000.00 |
| Sep 30, 2025 | 502,000.00 |
| Jun 30, 2025 | 502,000.00 |
| Jun 30, 2025 | 502,000.00 |
| Mar 31, 2025 | 504,000.00 |
| Mar 31, 2025 | 504,000.00 |
| Dec 31, 2024 | 503,000.00 |
| Dec 31, 2024 | 503,000.00 |
| Sep 30, 2024 | 500,000.00 |
| Sep 30, 2024 | 500,000.00 |
| Jun 30, 2024 | 494,000.00 |
| Jun 30, 2024 | 494,000.00 |
| Mar 31, 2024 | 490,000.00 |
| Mar 31, 2024 | 490,000.00 |
| Dec 31, 2023 | 489,000.00 |
| Dec 31, 2023 | 489,000.00 |